Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
View ORCID ProfileStéphane Le Vu, View ORCID ProfileMarion Bertrand, View ORCID ProfileMarie-Joëlle Jabagi, View ORCID ProfileJérémie Botton, View ORCID ProfileAlain Weill, View ORCID ProfileRosemary Dray-Spira, View ORCID ProfileMahmoud Zureik
doi: https://doi.org/10.1101/2022.07.31.22278064
Stéphane Le Vu
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marion Bertrand
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marie-Joëlle Jabagi
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Jérémie Botton
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
2Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France
Alain Weill
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Rosemary Dray-Spira
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Mahmoud Zureik
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
3University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France

Data Availability
According to data protection and the French regulation, the authors cannot publicly release the data from the French national health data system (SNDS). However, any person or structure, public or private, for-profit or non-profit, is able to access SNDS data upon authorization from the French Data Protection Office (CNIL Commission Nationale de l'Informatique et des Libertes) to carry out a study, a research, or an evaluation of public interest (https://www.snds.gouv.fr/SNDS/Processus-d-acces-aux-donnees and https://www.indsante.fr/).
Posted August 01, 2022.
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
Stéphane Le Vu, Marion Bertrand, Marie-Joëlle Jabagi, Jérémie Botton, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
medRxiv 2022.07.31.22278064; doi: https://doi.org/10.1101/2022.07.31.22278064
Subject Area
Subject Areas
- Addiction Medicine (227)
- Allergy and Immunology (500)
- Anesthesia (110)
- Cardiovascular Medicine (1230)
- Dermatology (147)
- Emergency Medicine (282)
- Epidemiology (10005)
- Gastroenterology (497)
- Genetic and Genomic Medicine (2445)
- Geriatric Medicine (236)
- Health Economics (479)
- Health Informatics (1635)
- Health Policy (751)
- Hematology (248)
- HIV/AIDS (531)
- Medical Education (251)
- Medical Ethics (74)
- Nephrology (267)
- Neurology (2273)
- Nursing (139)
- Nutrition (350)
- Oncology (1244)
- Ophthalmology (375)
- Orthopedics (133)
- Otolaryngology (226)
- Pain Medicine (154)
- Palliative Medicine (50)
- Pathology (324)
- Pediatrics (729)
- Primary Care Research (282)
- Public and Global Health (4824)
- Radiology and Imaging (833)
- Respiratory Medicine (650)
- Rheumatology (283)
- Sports Medicine (225)
- Surgery (266)
- Toxicology (44)
- Transplantation (124)
- Urology (99)